The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease

Context  Aldosterone has emerged as an important mediator of disease progression and mortality in patients with chronic heart and kidney disease (CKD). Despite the increasing use of mineralocorticoid receptor antagonists in these patients, little is known about the effects on corticosteroid hormone secretion and metabolism.

[1]  J. Townend,et al.  Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. , 2009, Journal of the American College of Cardiology.

[2]  T. Olsson,et al.  Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. , 2009, The Journal of clinical endocrinology and metabolism.

[3]  B. Rutkowski,et al.  Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  C. Pryce.  Postnatal ontogeny of expression of the corticosteroid receptor genes in mammalian brains: Inter-species and intra-species differences , 2008, Brain Research Reviews.

[5]  N. Samani,et al.  Phenotypic consequences of variation across the aldosterone synthase and 11‐beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study , 2007, Clinical endocrinology.

[6]  M. Cooper,et al.  11β-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function* , 2007, Journal of Biological Chemistry.

[7]  H. Nagaraja,et al.  Usual ACE Inhibitor Therapy in CKD Patients Is Associated with Lower Plasma Aldosterone Levels than Usual Angiotensin Receptor Blocker Therapy , 2007, Kidney and Blood Pressure Research.

[8]  Stefan Störk,et al.  Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure , 2007, Circulation.

[9]  H. Raff,et al.  Association of Adrenal Steroids With Hypertension and the Metabolic Syndrome in Blacks , 2007, Hypertension.

[10]  F. Manguso,et al.  Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  P. Stewart,et al.  Cortisol metabolism in hypertension. , 2006, Best practice & research. Clinical endocrinology & metabolism.

[12]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[13]  J. Mann,et al.  Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. , 2005, Presse medicale.

[14]  D. Zehnder,et al.  Expression of renal 11β-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function , 2005 .

[15]  T. Mune,et al.  [Syndrome of apparent mineralocorticoid excess]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[16]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[17]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[18]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[19]  D. Duprez,et al.  Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.

[20]  S. Grottoli,et al.  The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  B. Walker,et al.  Glucocorticoid metabolism and the Metabolic Syndrome: associations in an elderly cohort. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[22]  F. Frey,et al.  Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. , 2002, Kidney international.

[23]  P. Manunta,et al.  CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. , 2000, Hypertension.

[24]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[25]  I. Heuser,et al.  Increased activity of the hypothalamus–pituitary–adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone , 2000, Psychoneuroendocrinology.

[26]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[27]  F. Frey,et al.  Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. , 1999, The Journal of clinical endocrinology and metabolism.

[28]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[29]  H. Akil,et al.  The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. , 1998, The Journal of clinical endocrinology and metabolism.

[30]  M. Joëls,et al.  Brain corticosteroid receptor balance in health and disease. , 1998, Endocrine reviews.

[31]  C. Shackleton,et al.  Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man , 1996, Clinical endocrinology.

[32]  J. Born,et al.  Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. , 1993, Neuroendocrinology.

[33]  J. Mathis,et al.  Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. , 1993, Endocrinology.

[34]  F. Holsboer,et al.  Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. , 1993, Molecular endocrinology.

[35]  R. Sapolsky,et al.  The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. , 1991, Endocrine reviews.

[36]  J. Whitworth,et al.  THE KIDNEY IS THE MAJOR SITE OF CORTISONE PRODUCTION IN MAN , 1989, Clinical endocrinology.

[37]  C. Edwards,et al.  Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. , 1988, The Journal of clinical investigation.

[38]  D. Housman,et al.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.

[39]  D. Webb,et al.  Measurement of plasma angiotensin II. , 1985, Clinical science.

[40]  J. Morton,et al.  A microassay for active and total renin concentration in human plasma based on antibody trapping. , 1980, Clinica chimica acta; international journal of clinical chemistry.

[41]  W. Sadee,et al.  Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. , 1976, Endocrinology.

[42]  J. Jarrell,et al.  Mechanism of action of spironolactone on adrenocortical function in guinea pigs. , 1976, The Journal of pharmacology and experimental therapeutics.

[43]  D. Zehnder,et al.  Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. , 2005, European journal of endocrinology.

[44]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[45]  E. Arvat,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans* , 2022 .